NEW YORK, Oct. 8, 2018 /PRNewswire/ -- Global Orphan and
Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive
Landscape as New Companies Enter the Market with Novel Products,
Driving Strong Market Growth
Read the full report: https://www.reportlinker.com/p05582513
Summary
Dermatology is a highly diverse therapy area, in terms of severity
and clinical presentation, which deals with diseases of the skin,
hair and nails. Whilst an orphan disease is a disease that is
neglected in terms of research and funding and in the US, a disease
is considered to be rare if it affects fewer than 200,000
people.
Many orphan and rare dermatology disorders are associated with
significant quality of life impairments, particularly if the
disease is insufficiently controlled. In particular, disease
visibility can have a profoundly negative impact on patient
confidence. However, the current therapeutics market is a highly
genericized therapy area and there exists a significant unmet need
for more efficacious and safer treatment options that treat the
underlying causes of disease as opposed to managing the
symptoms.
This report covers all orphan and rare dermatology disorders, but
there is a particular focus on six key diseases, systemic sclerosis
(scleroderma), alopecia, epidermolysis bullosa, pemphigus vulgaris,
vitiligo and cutaneous lupus erythematosus, as these conditions
have the largest pipelines within the therapy area.
The premium product market size for orphan and rare dermatology
therapeutics was valued at $1.64
billion in 2017 and it is expected to grow at a compound
annual growth rate (CAGR) of 20.5% to $6.07
billion in 2024.
Scope
- The orphan and rare dermatology market landscape is expected to
change and grow. Novel targets are expected to enter the market and
drive market growth with a move towards disease modifying drugs
instead of drugs which manage symptoms.
- Overall, there are 262 orphan and rare dermatology products in
the pipeline.
- Which molecular targets are most prominent within the
pipeline?
- How do the key indications differ in terms of molecule type?
- How does the composition of the pipeline compare with that of the
existing market?
- What mechanisms of action are most common for pipeline drugs?
- The premium products market size for orphan and rare dermatology
therapeutics is expected to grow, from $1.64
billion in 2017 to $6.07
billion in 2024, at a CAGR of 20.5%.
- Which products will contribute to market growth most, and will
any achieve blockbuster status?
- Will the current market leaders retain their dominance over the
forecast period, and how is their revenue share of the orphan and
rare dermatology market set to change?
- What CAGR will these companies register in the forecast
period?
- How many strategic consolidations have been completed in the past
decade?
- Which types of assets attract the largest deal values?
Reasons to buy
- Understand the current clinical and commercial landscape by
considering disease pathogenesis, diagnosis, prognosis and the
treatment options available at each stage of diagnosis for the six
key indications.
- Visualize the composition of the orphan and rare dermatology
market overall and across each key indication, in terms of dominant
molecule types and targets, highlighting the key commercial assets
and players.
- Identify trends and developments, in terms of molecule type and
molecular target, within the overall orphan and rare dermatology
pipeline, as well as for each of the six key indications.
- Understand the growth in patient epidemiology and market revenues
for the orphan and rare dermatology market globally, and across the
key players and product types.
- Consider market opportunities and potential risks by examining
the incentives and challenges of drug development within the orphan
market space and the trends in clinical trial duration and size, as
well as clinical trial failure rates, by stage of development,
molecule type and molecular target.
- Recognize how the evolving treatment landscape will drive market
growth to 2024 and understand the contributions that different
products, molecular targets and companies will make to this
growth.
- Identify commercial opportunities in the orphan and rare
dermatology deals landscape by analyzing trends in licensing and
co-development deals.
Read the full report: https://www.reportlinker.com/p05582513
About Reportlinker
ReportLinker is an award-winning market research solution.
Reportlinker finds and organizes the latest industry data so you
get all the market research you need - instantly, in one place.
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
View original
content:http://www.prnewswire.com/news-releases/global-orphan-and-rare-dermatology-drugs-market-to-2024---an-increasingly-competitive-landscape-as-new-companies-enter-the-market-with-novel-products-driving-strong-market-growth-300727020.html
SOURCE Reportlinker